Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of TNX-102 SL Taken Daily At Bedtime In Patients With Fibromyalgia

Next Previous
X
Search
Trial Profile

A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of TNX-102 SL Taken Daily At Bedtime In Patients With Fibromyalgia

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclobenzaprine (Primary)
  • Indications Fibromyalgia; Pain
  • Focus Registrational; Therapeutic Use
  • Acronyms RALLY
  • Sponsors Tonix Pharmaceuticals Inc

    • Most Recent Events

    • 21 Mar 2022 Results presented in the Tonix Pharmaceuticals Holding Corp Media Release.
    • 14 Mar 2022 According to a Tonix Pharmaceuticals Holding Corp media release, company plans to employ pharmacogenomic (PGx) techniques to compare the RALLY and RELIEF study populations, which may provide a path to precision medicine-based companion diagnostics for TNX-102 SL in FM.
    • 14 Mar 2022 According to a Tonix Pharmaceuticals Holding Corp media release, topline results are expected in the first quarter of 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top